AC Immune SA trades as part of the healthcare sector and biotechnology industry. The company CEO is Andrea Pfeifer. AC Immune SA is a clinical stage biopharmaceutical company. It discovers, designs and develops novel, proprietary medicines for treatment of neurodegenerative diseases with the help of proprietary platforms.

Previous Intraday Performance:

The ACIU shares had a previous change of 3.71% which opened at 4.83 and closed at 5.03. It moved to an intraday high of 5.04 and a low of 4.83.

SeekingAlpha:  AC Immune reports Q1 results

Historical Performance:

Over the last five trading days, ACIU shares returned 2.86% and in the past 30 trading days it returned 1.41%. Over three months, it changed 19.48%. In one year it has changed -51.20% and within that year its 52 week high was 17.40 and its 52 week low was 3.25. ACIU stock is 54.77% above its 52 week low.

Our calculations result in a 200 day moving average of 7.46 and a 50 day moving average of 4.89. Right now, ACIU stock is trading -32.62% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  AC Immune reports Q1 results


The company has a market cap of $339.8m with 67.6m shares outstanding and a float of 67.6m shares. Trading volume was 78,199 shares and has experienced an average volume of 216,194 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for AC Immune SA was -0.83 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is 1.33.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019 0.91
4thQtr 2018 -0.21
3rdQtr 2018 -0.22
2ndQtr 2018 -0.19
1stQtr 2018 -0.21

Base on our calculations, the intrinsic value per share is 28.50, which means it might be undervalued and has a margin of safety of 82.35%.

The long-term trend of the EPS is a vital number as it helps understand the future potential of AC Immune SA; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been 225.60% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 43.50% of institutional ownership.

The beta was calculated to be -0.11.

SeekingAlpha:  Achillion’s ACH-4471 shows encouraging action in PNH study; shares ahead 7% premarket

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is 14.16%, return on assets is 11.36%, profit margin is 30.85%, price-to-sales is 4.03 and price-to-book is 1.41.

Company Score Card:

Results are out of six:
 1  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 5  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here